Uncategorized
VIDEO: Sirolimus reduces vitreous haze in patients with posterior uveitis
BALTIMORE – Phase 3 studies of intravitreal sirolimus demonstrated reduced vitreous haze in patients with noninfectious posterior uveitis, Peter K. Kaiser, MD, reported at the Association for Research in Vision and Ophthalmology meeting here. The drug is under FDA review.